原发鼻腔T/NK-T细胞非霍奇金淋巴瘤34例临床分析

 目的 探讨原发鼻腔T细胞性非霍奇金淋巴瘤（NHL）的临床特点及治疗。方法 回顾分析1997年1月至2001年12月收治的鼻腔T细胞性NHL34例。其中23例用化、放疗联合治疗，9例用单纯化疗，2例未治疗。所有化疗均采用标准CHOP方案。结果 单纯化疗组有效率为44.4 ％，CR率为22.2 ％；化、放联合治疗组有效率为100.0 ％，CR率86.9 ％。全组1年、3年、5年生存率分别为52.9 ％，41.2 ％，18.3 ％。化、放联合治疗组5年生存率高于单纯化疗组；局限于鼻腔（ⅠE期）者，5年生存率高于有远处播散者（>ⅠE期）。结论 原发性鼻腔T细胞NHL 预后不良,用标准CHOP方案化疗疗效差，联合化、放疗有助于改善预后。

Clinical analysis of 34 patients with nasal cavity T-cell non-Hodgkin lymphoma

Objective To investigate the clinical feature and treatment options of primary nasal cavity T-cell non-Hodgkin lymphoma(NHL). Methods From January 1997 to December 2001,34 patients primary nasal cavity T-cell NHL were treated in our hospital. Twenty three patients were treated by chemotherapy plus radiotherapy,9 patients chemotherapy alone,two patients had no treatment. All patients received chemotherapy of CHOP regimen. Results The response rates(RR) of chemotherapy alone were 44.4 %, complete remission (CR) rates were 22.2 %; the response rates of chemotherapy plus radiotherapy were 100.0 %, CR rates were 86.9 %. The 1, 3, 5 year overall survival rates were 52.9 %, 41.2 % and 18.3 %, respectively. The 5 year overall survival rates of chemotherapy plus radiotherapy were higher than chemotherapy alone; The survival of the patients with localized disease was longer than the disseminated. Conclusion Treatment outcomes of nasal cavity T-cell non-Hodgkin lymphoma was unsatisfactory; Effectivenes of CHOP was limited; Combined chemotherapy with radiotherapy may improve survival. Further investigation is warranted.